Egyptian Board Clinical Pathology common mistakes
Egyptian Board Clinical Pathology · Understand the traps and how to avoid them.
In chemical pathology, when interpreting an arterial blood gas, the candidate calculates the anion gap without adjusting for hypoalbuminaemia, leading to a falsely normal gap and missing a high anion gap metabolic acidosis.
Candidates memorise the formula (Na+ − [Cl− + HCO3−]) but forget that albumin is the major unmeasured anion; in hypoalbuminaemic patients (e.g., nephrotic syndrome, cirrhosis, critical illness) the gap is artificially lowered, masking conditions such as lactic acidosis or ketoacidosis.
What to do instead
Always correct the anion gap for albumin: corrected AG = measured AG + 2.5 × (4.0 − albumin g/dL). Practise with clinical vignettes that include low albumin and a metabolic acidosis, and state the corrected value explicitly in your answer.
In haematology, the candidate evaluates a normocytic anaemia without ordering or correctly interpreting the reticulocyte count, and therefore misclassifies a hypoproliferative marrow failure as a destructive haemolytic process (or vice versa).
The reticulocyte count is the first branching point in anaemia classification, but candidates under time pressure jump from MCV to a diagnosis based on morphology alone, or they confuse reticulocyte percentage with the absolute reticulocyte count and the corrected count.
What to do instead
For every anaemia question, calculate the absolute reticulocyte count (RBC × reticulocyte % / 100) and the reticulocyte production index (RPI = absolute retic / maturation factor). Use RPI <2 to indicate hypoproliferation and >2 to indicate increased destruction or blood loss. Drill this in every anaemia case until it is automatic.
In transfusion medicine, the candidate interprets a positive antibody screen as proof of a clinically significant alloantibody without performing or interpreting the antibody identification panel, and fails to distinguish alloimmunisation from autoantibody or rouleaux.
Candidates learn the antibody screen as a yes/no test, but the screen only detects the presence of an unexpected antibody. Without the identification panel (enzyme-treated cells, selected cells, autocontrol), they cannot determine specificity or clinical significance, and they overlook that a positive autocontrol suggests an autoantibody or non-immune cause.
What to do instead
Work through the full serological algorithm: screen → autocontrol → panel → selected cells/enzymes → adsorption if needed. For each positive screen, state whether the autocontrol is positive or negative, which antibody specificity is suggested by the reaction pattern, and whether the antibody is clinically significant (e.g., anti-Jka vs anti-Lewis). Practise with paper panels.
In medical microbiology, the candidate selects an antibiotic for a culture-confirmed infection based on the organism name alone, without checking the susceptibility report, and recommends a drug to which the isolate is resistant (e.g., ampicillin for a beta-lactamase-producing Haemophilus influenzae or Escherichia coli).
Candidates conflate empirical therapy with directed therapy. They memorise 'first-line' drugs for organisms but forget that resistance mechanisms (ESBL, MRSA, AmpC) are common and that the laboratory susceptibility result is the definitive guide once available.
What to do instead
For any culture-positive scenario, explicitly state: (1) the organism, (2) the susceptibility pattern from the report, and (3) the directed drug chosen and why. If the susceptibility report is not given, state that empirical therapy is required and list the local resistance rates that would guide the choice. Never recommend a drug without linking it to the susceptibility data.
In infectious disease serology, the candidate interprets a single positive IgM result as diagnostic of acute infection without considering cross-reactivity, persistence, or the need for confirmatory testing (e.g., diagnosing acute toxoplasmosis or CMV from IgM alone in a pregnant woman).
Candidates treat IgM as a binary 'acute infection' marker, ignoring that IgM can persist for months to years, can be falsely positive due to rheumatoid factor or cross-reacting antibodies, and that IgG avidity testing is required to date infection.
What to do instead
For every serology question, apply the triad: paired sera (acute and convalescent) showing seroconversion or a fourfold rise in IgG; IgM confirmed by a second method (e.g., ELISA confirmed by immunofluorescence or immunoblot); and IgG avidity to distinguish recent from past infection. State explicitly that a single IgM is insufficient and name the confirmatory test you would request.
In clinical immunology, the candidate diagnoses a primary immunodeficiency based on a low immunoglobulin level alone, without confirming that the patient has had appropriate antigen exposure and without excluding secondary causes (nephrotic syndrome, protein-losing enteropathy, drugs, malignancy).
Candidates memorise 'low IgG = antibody deficiency' but forget that immunoglobulin levels are affected by protein loss, malnutrition, and immunosuppressive drugs, and that a diagnosis of common variable immunodeficiency requires exclusion of secondary causes plus impaired specific antibody responses.
What to do instead
Before labelling a primary immunodeficiency, systematically exclude secondary causes (urine protein, albumin, liver function, medication history, malignancy screen) and demonstrate functional antibody deficiency (poor response to vaccination, e.g., pneumococcal or tetanus). State the diagnostic criteria you are applying and the tests needed to confirm them.
In histopathology and cytopathology, the candidate reports a cytology specimen as 'negative for malignancy' without acknowledging the limitations of the sample (e.g., scanty cellularity, obscuring blood, no diagnostic cells), thereby giving false reassurance.
Candidates focus on finding malignant cells and forget that adequacy is a separate and equally important judgement. A paucicellular or poorly preserved sample cannot exclude malignancy, and failure to state this is a recognised cause of diagnostic error.
What to do instead
For every cytology question, first assess and state adequacy (cellularity, preservation, presence of the relevant cell population). If inadequate, report 'unsatisfactory for evaluation' and recommend repeat or ancillary testing. If adequate but negative, state the negative predictive value limitations and the need for clinical and radiological correlation.
In laboratory genetics and molecular diagnostics, the candidate interprets a variant of uncertain significance (VUS) as pathogenic and recommends cascade testing or risk-reducing surgery for family members.
Candidates equate 'variant detected' with 'mutation found'. They do not apply the ACMG/AMP classification framework and do not appreciate that most VUS are reclassified as benign, so acting on them causes harm.
What to do instead
For every variant, state the ACMG/AMP category (pathogenic, likely pathogenic, VUS, likely benign, benign) and the evidence used (population frequency, computational prediction, functional data, segregation). For a VUS, explicitly state that it should not be used for clinical decision-making, and recommend referral to a genetics service and periodic reclassification review.
In laboratory management and quality assurance, the candidate describes corrective action for a failed external quality assessment (EQA) or internal quality control (IQC) event as 'repeat the test and document the result' without performing root cause analysis or verifying that the problem is fixed.
Candidates treat quality failures as documentation exercises rather than as opportunities to identify systemic causes. They omit the steps required by ISO 15189: investigation, identification of root cause, corrective action, effectiveness check, and, where relevant, notification of affected results.
What to do instead
Use a structured framework for every QC/EQA failure: (1) immediate containment (stop reporting, quarantine results), (2) root cause analysis (fishbone or 5-whys: reagent, calibrator, operator, equipment, environment), (3) corrective action, (4) effectiveness check (repeat QC/EQA over defined period), (5) look-back at patient results if affected, and (6) documentation and management review. Name each step explicitly in your answer.
In laboratory safety, ethics and professional practice, the candidate discusses a needlestick injury or a critical result disclosure without addressing the mandatory reporting, consent, and confidentiality obligations that apply in the Egyptian regulatory context.
Candidates focus on the clinical or technical aspect (e.g., HIV post-exposure prophylaxis) and forget that laboratory professionals have legal and ethical duties: reporting sharps injuries to occupational health, documenting in the incident system, obtaining informed consent before HIV testing, and disclosing critical results only to authorised clinicians through a documented process.
What to do instead
For every safety or ethics scenario, explicitly list: (1) immediate actions (first aid, PEP within the window), (2) mandatory reporting (occupational health, incident report, national notifiable disease requirements), (3) consent and confidentiality requirements (who may be told, what is documented), and (4) the documented communication pathway for critical results. Anchor each point to the relevant Egyptian law or accreditation standard where you know it; if unsure, state the principle rather than inventing a citation.